General Information of Drug (ID: DMI79JN)

Drug Name
SKF-96365 Drug Info
Synonyms
SK-96365; 1-[2-(4-methoxyphenyl)-2-[3-(4-methoxyphenyl)propoxy]ethyl]-1H-imidazole; 1-[2-(4-Methoxyphenyl)-2-[3-(4-methoxyphenyl)propoxy]ethyl]imidazole; 1-[beta-[3-(4-Methoxyphenyl)propoxy]-4-methoxyphenethyl]-1H-imidazole; 1-(2-(3-(4-Methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1H-imidazole; AC1L2XSB; SKF-96365 free base; Imidazole-based ligand, 15; KBioSS_000197; KBioGR_000197; BSPBio_001477; SCHEMBL722014; GTPL2441; CHEMBL258502; KBio3_000394; KBio2_000197; KBio3_000393; KBio2_005333; KBio2_002765; CHEBI:91847; BDBM21164
Indication
Disease Entry ICD 11 Status REF
Angina pectoris BA40 Terminated [1]
Cross-matching ID
PubChem CID
104955
ChEBI ID
CHEMBL145121
CAS Number
CAS 130495-35-1
TTD Drug ID
DMI79JN

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Nicardipine DMCDYW7 High blood pressure BA00 Approved [3]
Clevidipine butyrate DMW4M97 Hypertension BA00-BA04 Approved [4]
Nisoldipine DM7ISKJ Hypertension BA00-BA04 Approved [5]
Felodipine DMOSW35 Hypertension BA00-BA04 Approved [6]
Nimodipine DMQ0RKZ Cerebral vasospasm BA85.Z Approved [7]
Bepridil DM0RKS4 Chronic/stable angina BA40.1 Approved [8]
Isradipine DMA5XGH Hypertension BA00-BA04 Approved [8]
DIPROTEVERINE HYDROCHLORIDE DMG8U6M Angina pectoris BA40 Phase 3 [9]
ATI-2042 DMWP59B Atrial fibrillation BC81.3 Phase 2 [10]
HBI-3000 DM74ZKN Heart arrhythmia BC65 Phase 2 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Calcium channel unspecific (CaC) TT5HONZ NOUNIPROTAC Modulator [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2441).
2 The transient receptor potential channel antagonist SKF96365 is a potent blocker of low-voltage-activated T-type calcium channels. Br J Pharmacol. 2010 Jul;160(6):1464-75.
3 Effect of intracoronary nicardipine on cardiac enzymes after elective percutaneous coronary intervention. Clin Cardiol. 2009 Jun;32(6):315-20.
4 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
5 RT-PCR and pharmacological analysis of L-and T-type calcium channels in rat carotid body. Adv Exp Med Biol. 2009;648:105-12.
6 Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. J Pharmacol Exp Ther. 2009 Feb;328(2):621-7.
7 Influence of bupropion and calcium channel antagonists on the nicotine-induced memory-related response of mice in the elevated plus maze. Pharmacol Rep. 2009 Mar-Apr;61(2):236-44.
8 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
9 Prenatal toxicity studies in rats and rabbits with the calcium channel blocker diproteverine. Reprod Toxicol. 1996 Jan-Feb;10(1):43-9.
10 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
11 Electrophysiological properties of HBI-3000: a new antiarrhythmic agent with multiple-channel blocking properties in human ventricular myocytes. J Cardiovasc Pharmacol. 2011 Jan;57(1):79-85.